Combined Inhibition of Specific Sirtuins as a Potential Strategy to Inhibit Melanoma Growth
Open Access
- 16 October 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 591972
Abstract
Combined Inhibition of Specific Sirtuins as a Potential Strategy to Inhibit Melanoma GrowthKeywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR059130, P30AR066524)
- U.S. Department of Veterans Affairs (IK6BX003780)
This publication has 42 references indexed in Scilit:
- Sirtuin-3 (SIRT3) and the Hallmarks of CancerGenes & Cancer, 2013
- A Molecular Mechanism for Direct Sirtuin Activation by ResveratrolPLOS ONE, 2012
- SIRT3, a pivotal actor in mitochondrial functions: metabolism, cell death and agingBiochemical Journal, 2012
- Sirtuins and Disease: The Road AheadFrontiers in Pharmacology, 2012
- SIRT1, metabolism and cancerCurrent Opinion in Oncology, 2012
- SIRT3 Opposes Reprogramming of Cancer Cell Metabolism through HIF1α DestabilizationCancer Cell, 2011
- The Critical Role of the Class III Histone Deacetylase SIRT1 in CancerCancer Research, 2009
- Mammalian Sir2 Homolog SIRT3 Regulates Global Mitochondrial Lysine AcetylationMolecular and Cellular Biology, 2007
- The genome and epigenome of malignant melanomaAPMIS, 2007
- Calorie restriction, SIRT1 and metabolism: understanding longevityNature Reviews Molecular Cell Biology, 2005